Cooley advised the underwriters on Syndax’s $57.7 million initial public offering. The company now trades on the NASDAQ Global Select Market under the symbol “SNDX.”

Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple negative breast cancer.

Morgan Stanley & Co. LLC and Citigroup Global Markets Inc. acted as lead book-running managers for the offering. JMP Securities LLC and Oppenheimer & Co. Inc. acted as co-managers.

The Cooley corporate and securities team advising the underwriters included Dave Peinsipp, Div Gupta, Josh Kaufman, Pia Kaur and Susan Walker.


Related Posts:

Leave a Reply